R. Maini, F. Breedveld, J. Kalden, J. Smolen, D. Davis et al., Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, Arthritis & Rheumatism, vol.6, issue.9, pp.1552-1563, 1998.
DOI : 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W

J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten et al., Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial, Arthritis & Rheumatism, vol.14, issue.Suppl 9, pp.2224-2233, 2003.
DOI : 10.1002/art.11104

D. Van-der-heijde, B. Dijkmans, P. Geusens, J. Sieper, K. Dewoody et al., Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT) Arthritis Rheum, pp.582-591, 2005.

K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M. Kapetanovic et al., Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor ?? inhibitor infliximab, Arthritis & Rheumatism, vol.45, issue.12, pp.3782-3789, 2006.
DOI : 10.1002/art.22214

G. Wolbink, M. Vis, W. Lems, A. Voskuyl, E. De-groot et al., Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis, Arthritis & Rheumatism, vol.86, issue.3, pp.711-715, 2006.
DOI : 10.1002/art.21671

M. De-vries, G. Wolbink, S. Stapel, H. De-vrieze, J. Van-denderen et al., Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation, Annals of the Rheumatic Diseases, vol.66, issue.9, pp.1252-1254, 2007.
DOI : 10.1136/ard.2007.072397

R. Krzysiek, M. Breban, P. Ravaud, M. Prejean, J. Wijdenes et al., Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: Results from a randomized control study, Arthritis & Rheumatism, vol.4, issue.5, pp.569-576, 2009.
DOI : 10.1002/art.24275

B. Fautrel, T. Pham, G. Mouterde, L. Loët, X. Goupille et al., Recommendations of the French Society for Rheumatology regarding TNF?? antagonist therapy in patients with rheumatoid arthritis, Joint Bone Spine, vol.74, issue.6, pp.627-637, 2007.
DOI : 10.1016/j.jbspin.2007.10.001

T. Pham, B. Fautrel, E. Dernis, P. Goupille, F. Guillemin et al., Recommendations of the French Society for Rheumatology regarding TNF?? antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update, Joint Bone Spine, vol.74, issue.6, pp.638-646, 2007.
DOI : 10.1016/j.jbspin.2007.10.003

D. Ternant, D. Mulleman, D. Degenne, S. Willot, J. Guillaumin et al., An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Infliximab, Therapeutic Drug Monitoring, vol.28, issue.2, pp.169-174, 2006.
DOI : 10.1097/01.ftd.0000189901.08684.4b

G. Van-assche, C. Magdelaine-beuzelin, D. Haens, G. Baert, F. Noman et al., Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial, Gastroenterology, vol.134, issue.7, pp.1861-1868, 2008.
DOI : 10.1053/j.gastro.2008.03.004

D. Mulleman, J. Méric, G. Paintaud, E. Ducourau, C. Magdelaine-beuzelin et al., Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis, Arthritis Research & Therapy, vol.11, issue.6, p.178, 2009.
DOI : 10.1186/ar2867
URL : https://hal.archives-ouvertes.fr/hal-00616867

Z. Xu, K. Seitz, A. Fasanmade, J. Ford, P. Williamson et al., Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis, The Journal of Clinical Pharmacology, vol.26, issue.suppl 28, pp.681-695, 2008.
DOI : 10.1177/0091270008316886

D. Ternant, A. Aubourg, C. Magdelaine-beuzelin, D. Degenne, H. Watier et al., Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients, Therapeutic Drug Monitoring, vol.PAP, pp.523-529, 2008.
DOI : 10.1097/FTD.0b013e318180e300
URL : https://hal.archives-ouvertes.fr/hal-00616549

G. Bartelds, C. Krieckaert, M. Nurmohamed, P. Van-schouwenburg, W. Lems et al., Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up, JAMA, vol.305, issue.14, pp.1460-1468, 2011.
DOI : 10.1001/jama.2011.406

M. Breban, P. Ravaud, P. Claudepierre, G. Baron, Y. Henry et al., Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment, Arthritis & Rheumatism, vol.54, issue.1, pp.88-97, 2008.
DOI : 10.1002/art.23167
URL : https://hal.archives-ouvertes.fr/inserm-00217374

D. Mulleman, C. M. Lin, D. Ducourau, E. Emond, P. Ternant et al., Trough Infliximab Concentrations Predict Efficacy and Sustained Control of Disease Activity in Rheumatoid Arthritis, Therapeutic Drug Monitoring, vol.32, pp.232-236, 2010.
DOI : 10.1097/FTD.0b013e3181cc6fef
URL : https://hal.archives-ouvertes.fr/hal-00616781

C. Miow-lin, D. Mulleman, D. Azzopardi, N. Griffoul-espitalier, I. Valat et al., Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis, Scandinavian Journal of Rheumatology, vol.44, issue.1, pp.97-98, 2010.
DOI : 10.1177/0091270008316886